Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Vasyl Kovalishyn"'
Autor:
Ivan Semenyuta, Diana Hodyna, Vasyl Kovalishyn, Bohdan Demydchuk, Maryna Kachaeva, Stepan Pilyo, Volodymyr Brovarets, Larysa Metelytsia
Publikováno v:
Artificial Intelligence Chemistry, Vol 1, Iss 2, Pp 100024- (2023)
Here we describe the results of QSAR analysis based on artificial neural networks, synthesis, activity evaluation and molecular docking of a number of 1,3-oxazole derivatives as anti-E. coli antibacterials. All developed QSAR models showed excellent
Externí odkaz:
https://doaj.org/article/b7b407cb8adc4b28a282928c5d6375d3
Autor:
Vasyl Kovalishyn, Oleksandr Severin, Maryna Kachaeva, Oleksandr Kobzar, Kathy A. Keith, Emma A. Harden, Caroll B. Hartline, Scott H. James, Andriy Vovk, Volodymyr Brovarets
Publikováno v:
Molecular Biotechnology.
Autor:
Diana Hodyna, Vasyl Kovalishyn, Volodymyr Blagodatnyi, Svitlana Bondarenko, Galyna Mrug, Mykhaylo Frasinyuk, Larysa Metelytsia
Publikováno v:
Ukrainica Bioorganica Acta. 16:23-29
QSAR analysis of a 5143 compounds set of previously synthesized compounds tested against multi-drug resistant (MDR) clinical isolate Escherichia coli strains was done by using Online Chemical Modeling Environment (OCHEM).The predictive ability of the
Autor:
Vasyl Kovalishyn, Kathy A. Keith, Emma A. Harden, Maryna V. Kachaeva, Kostiantyn Ziabrev, Volodymyr Zyabrev, Volodymyr Brovarets, Caroll B. Hartline, Scott H. James
Publikováno v:
Journal of Computer-Aided Molecular Design. 35:1177-1187
The problem of designing new antiviral drugs against Human Cytomegalovirus (HCMV) was addressed using the Online Chemical Modeling Environment (OCHEM). Data on compound antiviral activity to human organisms were collected from the literature and uplo
Autor:
Svitlana V. Shishkina, I. O. Yaremchuk, Vasyl Kovalishyn, Anna M. Zinchenko, Ivan V. Semenyuta, Diana Hodyna, L. V. Muzychka, Oleg B. Smolii, Larysa Metelytsia, Evgenii V. Verves
Publikováno v:
Chemical Biology & Drug Design. 100:1025-1032
Predictive QSAR models for the search of new adenosine A2A receptor antagonists were developed by using OCHEM platform. The predictive ability of the regression models has coefficient of determination q2 = 0.65-0.71 with cross-validation and independ
Autor:
Sergiy Rogalsky, Volodymyr Blagodatny, Ivan V. Semenyuta, Larysa Metelytsia, Vasyl Kovalishyn, Diana Hodyna
Publikováno v:
Current Bioactive Compounds. 17:130-144
Background: Escherichia coli especially its multiresistant strains as the common foodborne pathogens cause bloodstream infections, nosocomial pneumonia, infections of the skin and soft tissues. Therefore, the search for new effective biologically act
Autor:
Larysa Metelytsia, Volodymyr Brovarets, Volodymyr Blagodatny, V. O. Sinenko, Ivan V. Semenyuta, Gennady Poda, S. R. Slivchuk, Diana Hodyna, Vasyl Kovalishyn
Publikováno v:
Current Drug Discovery Technologies. 17:365-375
Background: Tuberculosis (TB) is an infection disease caused by Mycobacterium tuberculosis (Mtb) bacteria. One of the main causes of mortality from TB is the problem of Mtb resistance to known drugs. Objective: The goal of this work is to identify po
Autor:
Oleksandr L. Kobzar, O.P. Trokhimenko, Vasyl Kovalishyn, O.V. Muzychka, V. O. Sinenko, Diana Hodyna, S. R. Slivchuk
Publikováno v:
Reports of the National Academy of Sciences of Ukraine. :70-77
Autor:
Liubov V, Muzychka, Evgenii V, Verves, Iryna O, Yaremchuk, Anna M, Zinchenko, Svitlana V, Shishkina, Ivan V, Semenyuta, Diana M, Hodyna, Larysa O, Metelytsia, Vasyl, Kovalishyn, Oleg B, Smolii
Publikováno v:
Chemical biologydrug designREFERENCES. 100(6)
Predictive QSAR models for the search of new adenosine A
Autor:
Larisa O. Metelytsia, Maryna V. Kachaeva, Volodymyr Brovarets, Oleksandr L. Kobzar, Vasyl Kovalishyn, Maria M. Trush, Alla D. Ocheretniuk
Publikováno v:
Current Drug Discovery Technologies. 16:204-209
Background: The incidence of invasive fungal infections caused by Candida spp. has increased continuously in recent decades, especially in populations of immunocompromised patients or individuals hospitalized with serious underlying diseases. Therefo